CJC-1295 research guide for Gåvsta. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Gåvsta looking to source CJC-1295, the first thing to know is that this compound moves through online research channels. What this means for Gåvsta researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those verification methods are within reach of all serious researchers. Separating quality CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Gåvsta researchers need to know about finding, evaluating, and storing CJC-1295 for legitimate research applications.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Gåvsta researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate prior to buying, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. For Gåvsta researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before placing larger orders is what experienced peptide researchers consistently do. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Gåvsta
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no pricing advantage justifies skipping this verification. The research literature on CJC-1295 should be studied thoroughly before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
